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Purinergic signaling has a crucial role in different vascular
processes. The endothelial-derived vasoconstrictor uridine
adenosine tetraphosphate (Up4A) is a potent activator of the
purinoceptor P2Y and is released under pathological
conditions. Here we sought to measure purinergic effects on
vascular calcification and initially found that Up4A plasma
concentrations are increased in patients with chronic kidney
disease. Exploring this further we found that exogenous
Up4A enhanced mineral deposition under calcifying
conditions ex vivo in rat and mouse aortic rings and in vitro in
rat vascular smooth muscle cells. The addition of Up4A
increased the expression of different genes specific for
osteochondrogenic vascular smooth muscle cells such as
Cbfa1, while decreasing the expression of SM22a, a marker
specific for vascular smooth muscle cells. The influence of
different P2Y antagonists on Up4A-mediated process
indicated that P2Y2/6 receptors may be involved. Mechanisms
downstream of P2Y signaling involved phosphorylation of
the mitogen-activated kinases MEK and ERK1/2. Thus, Up4A
activation of P2Y influences phenotypic transdifferentiation
of vascular smooth muscle cells to osteochondrogenic cells,
suggesting that purinergic signaling may be involved in
vascular calcification.
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Arteriosclerosis is an increasingly recognized consequence in
patients with chronic kidney disease (CKD).1 In patients with
CKD, both intima and media calcification occur in parallel.2
Media calcification preponderates already in early stages of
CKD.3 Large elastic and muscular vessels are prone to media
calcification and vascular stiffening, which is associated with
an increased cardiovascular morbidity and mortality.4 There-
fore, epidemiological studies have emphasized the fact of a
disturbed mineral metabolism and increased calcium-phos-
phate product.5 There are clear hints that arteriosclerosis is
an active, cell-regulated process in the media, starting with
local phenotypic transdifferentiation of vascular smooth
muscle cells (VSMCs) to osteochondrogenic cells (OCC).
OCCs typically express markers of both osteoblasts and
chondrocytes.6 As a consequence, the expression of genes
such as osteopontin (OPN),7 osteocalcin (OCN),8 and
alkaline phosphatase (ALP)9 is enhanced. Osteoprotegerin
(OPG), a regulator of bone metabolism, seems to be involved
in vascular calcification as well. OPG levels are increased in
plasma and calcified vessels;10–13 in contrast, animal studies
suggest a beneficial effect of OPG.14,15 Furthermore, OPG/
mice have increased calcification of the vessel wall.16
Therefore, both a suitable environment with a pathologi-
cal elevated calcium–phosphate product and a reprogram-
ming of vascular cells induced by direct receptor-mediated
processes seem to be essential for an enhanced vascular
calcification.17 Several factors, for example, oxidized LDL,
interleukin-4, and transforming growth factor-b, are known
to stimulate the transdifferentiation of VSMCs. An early step
is the induction of transcription factors,6 especially the core
binding factor a-1 (Cbfa1),18 Msx2,19 which is a homeobox-
containing transcription factor, and osterix (Osx),20 a zinc-
finger-containing transcription factor.
During the past several years, purinoceptors have been
recognized as important modulators of responses between
blood cells and cells of the vessel wall,21,22 addressing to
hypertension and vascular inflammation.23 In 2005, a highly
potent endothelial-derived contracting factor, uridine ade-
nosine tetraphosphate (Up4A), was identified,
24 which
activated purinoceptors.25
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Nucleotides provide highly localized and transient signals,
which regulate bone remodeling.26 Furthermore, there is
compelling evidence that nucleotides functioning via P2Y are
potent mediators in transcriptional signaling in osteoblasts.26
To our knowledge, nothing is known about the influence of
dinucleoside polyphosphates on vascular calcification. In this
study, we investigated the properties of VSMC calcification.
We provide evidence for a potent influence of Up4A and P2Y
activation on the phenotype transition of rat aortic VSMCs,
which might have relevance in vivo as well.
RESULTS
Up4A plasma concentration
First, we were interested to know whether Up4A levels in
CKD patients undergoing hemodialysis are higher in
comparison with healthy controls. We could show that
CKD patients have on average 5.2-fold higher Up4A plasma
concentration compared with healthy subjects (Figure 1a).
Interestingly, Up4A concentration in CKD patients varies
from low levels to levels higher than 160 nmol/l.
Ex vivo and in vitro mineralization
We examined the effect of Up4A on aortic calcification in an
ex vivo assay. Calcifying condition triggered by calcifying
medium (CM) led to a medial located mineralization
visualized by von Kossa and Alizarin red staining in aortic
rings incubated for 14 days. Co-treatment with Up4A
increased mineral deposition in the media (Figure 1b).
Decalcification of the aortic rings and subsequent quantifica-
tion of the calcium content approved these finding.
Incubation of the cells with CM significantly increased the
calcium content and co-treatment with Up4A elevated it in a
significant manner (Figure 1c).
Next, we investigated the effects of Up4A in vitro using rat
VSMCs. Incubation of VSMCs with CM induced a time-
dependent mineral deposition visualized by Alizarin red
staining after 7, 14, and 21 days. Up4A enhanced the
mineralization (Figure 2a). Cell viability was not affected by
Up4A (Supplementary Figure S2 online). Quantification of
the calcium content after decalcification of the cells showed a
significant increase after 28 and 31 days in the Up4A-treated
group compared with CM (Figure 2b). These results suggest
that Up4A is able to increase the calcification of VSMCs
ex vivo and in vitro.
VSMC transdifferentiation
Acquirement of an OCC phenotype is accompanied by down-
regulation of a-smooth muscle cell (a-SMC) actin. VSMCs
were cultivated in CM±Up4A, and the amount of a-SMC
actin with a fluorescein isothiocyanate (FITC)-conjugated
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Figure 1 |Up4A enhances calcification ex vivo. (a) Up4A plasma concentration of healthy controls (n¼ 15) and patients with chronic
kidney disease (CKD, n¼ 17) on hemodialysis (HD) treatment. (b) Staining of mineral deposits in aortic rings stimulated for 14 days as
indicated (Up4A: 10mmol/l) with Alizarin red or von Kossa staining. (c) Quantification of calcium content with O-cresolphthalein complexone
method of decalcified aortic rings incubated for 14 days as indicated (Up4A: 10mmol/l). The calcium concentration is normalized to dry
weight of the aortic rings. (a, c) Black bar graphs: control medium±Up4A: 10 mmol/l; white bar graphs: CM±Up4A: 10 mmol/l; mean±s.e.m.;
*Po0.05. CM, calcifying medium; Up4A, uridine adenosine tetraphosphate.
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monoclonal antibody compared with control conditions was
measured. Cultivation of the cells in CM decreases the amount
of FITC-positive cells compared with the control. In Up4A-co-
treated cells, the amount of a-SMC actin was further
diminished after 7 days compared with cells cultivated in CM
(Figure 3a). Quantification of FITC-positive cells via flow
cytometry affirmed these findings (Figure 3b). One prominent
phenotypic marker of osteoblastic differentiation is ALP.
Examination of ALP activity shows a time-dependent increase
in enzyme activity in cells cultivated in CM compared with
controls. Co-treatment of Up4A significantly enhanced ALP
enzyme activity in a time-dependent manner in compari-
son with CM alone, which shows a maximum after 21 days
(Figure 3c). Taken together, these results suggest that Up4A may
accelerate the calcification of rat VSMCs by enhancing ALP
enzyme activity and transdifferentiation.
Expression pattern
Phenotypic switch of VMSCs is attended by the expression of
genes characteristically for OCCs. The mRNA expression
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Figure 2 |Up4A enhances calcification in vitro. Vascular smooth muscle cells (VSMCs) were cultured for the indicated time points
in culture medium (control), CM, or CMþUp4A (10mmol/l). (a) Calcification of VSMCs was visualized with Alizarin red staining.
(b) Quantification of calcium content of the cell layers normalized to cellular protein content; mean±s.e.m.; *Po0.05 CMþUp4A versus CM.
CM, calcifying medium; Up4A, uridine adenosine tetraphosphate.
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detected by real-time PCR of Cbfa1, Msx2, osterix, and Sox9
significantly increased in a dose-dependent manner after
stimulation of the cells for 24 h with indicated concentrations
of Up4A (Figure 4a–d). Three other OCC-specific markers,
which are under the control of the transcription factor Cbfa1,
were investigated. The mRNA expression of OCN, an
inductor protein of osteoblast differentiation, is significantly
increased in a dose-dependent manner after Up4A treatment
of VSMCs after 48 h (Figure 4e). OPN and ALP mRNA
expression also dose-dependently increase after Up4A
stimulation (Figure 4f and g). Next, we investigated the
expression of OPG, an inhibitor of calcification, which dose-
dependently decreases after co-treatment with Up4A (Figure
4h). A marker for smooth muscle cell lineage—SM22a—
significantly decreases after Up4A treatment of the cells
(Figure 4i).
Besides expression of Cbfa1, the protein content signifi-
cantly increased in VMSCs treated with Up4A for 48 h,
respectively, as detected by western blot technique (Figure 5).
The bar graphs in Figure 5b show analysis of band intensity
of four independent experiments.
Activation of P2Y
We investigated the involvement of the receptors that might
be responsible for these effects. It is known that Up4A is able
to activate different P2Y subtypes25 that are expressed in
VSMCs (Supplementary Figure S1 online).27 Therefore, we
assessed the specific, non-selective P2Y antagonist suramin,
pyridoxal-phosphate-6-azophenyl-20,40-disulfonic acid
(PPADS), reactive blue-2 (RB-2), as well as the P2Y1
antagonist MRS2179 and the P2Y6 antagonist MRS2578.
The Up4A-induced Cbfa1 expression was significantly
decreased in the presence of suramin, PPADS, RB-2, and
MRS2578 (Figure 6a). To verify the involvement of the P2Y2,
we analyzed the effect of the stable ATP analog ATPgS, a
specific P2Y2 agonist. This agonist mimics the effect of Up4A
and stimulated Cbfa1 mRNA expression in a dose-dependent
manner (Figure 6b). As an agonist for P2Y6 we used ionosine
diphosphate which also significantly increased Cbfa1 expres-
sion. UTP activates both P2Y2 and P2Y4, and is able to
stimulate Cbfa1 expression (Figure 6c). Furthermore, the
inhibitory capacity of the antagonists used was tested for its
effect on ALP activity after 21 days. All mentioned anta-
gonists significantly diminished the CM±Up4A-induced
enzyme activity (Figure 6d). To verify the role of the most
prominent receptor subtype in VSMCs, the P2Y2, we used
aortic rings from P2Y2
/ and wild-type mice. In both cases,
CM significantly induced the increase in the calcium content,
but Up4A was only able to further increase the calcium
content in aortic rings from wild-type mice, whereas in
P2Y2
/, it decreased after 14 days of incubation (Figure 6e).
Intracellular signaling pathway
Previous studies showed that the MAP kinase (MAPK)
pathway is involved in the Cbfa1 regulation, and it is also
known to be involved in the downstream signaling of P2Y.
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Figure 3 |Up4A enhances the loss of SMC marker and the increase of OCC marker. Cells were cultured as indicated in control medium,
CM, or CMþUp4A (10mmol/l). (a, b) Immunofluorescent staining of the cells with a fluorescein isothiocyanate-conjugated anti-smooth
muscle cell-a-actin antibody, (a) detected by fluorescence microscopy and (b) quantified by flow cytometry (n¼ 5; mean±s.e.m.; *Po0.05).
(c) ALP enzyme activity was measured photometrically and normalized to cellular protein content; mean±s.e.m.; *Po0.05 CMþUp4A
versus CM. ALP, alkaline phosphatase; CM, calcifying medium; OCC, osteochondrogenic cell; SMC, smooth muscle cell; Up4A, uridine
adenosine tetraphosphate.
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We addressed whether Up4A is able to activate MEK and
ERK1/2 (ref. 27). Up4A led to a significant and time-
dependent increase of MEK and ERK1/2 phosphorylation
with a maximum increase after 10min (Figure 7a). Further-
more, we investigated the influence of the P2Y antagonists on
the phosphorylation of both MAPKs. The Up4A-induced
phosphorylation of MEK and ERK1/2 was significantly
decreased by suramin, PPADS, RB-2, and MRS2578 after
10min. The most potent inhibition is caused by suramin. As
controls, the specific MAPK inhibitors PD98059 and U0126
were used (Figure 7b). To verify the involvement of MAPK
phosphorylation in regulation of Cbfa1, we used Up4A
pretreatment with PD980529 and U0126 in Cbfa1 expression
study. Both inhibitors significantly decreased Up4A-induced
Cbfa1 expression (Figure 7c). There are hints in the literature
regarding the activation of Wnt3a and Wnt7a in the
calcification process.28 Here we could show that Up4A did
not activate Wnt3a and Wnt7a after 24 h of stimulation
(Supplementary Figure S3 online), whereas stimulation for
14 days with Up4A leads to an activation of both Wnt3a and
Wnt7a (Figure 7d). Figure 7e summarizes the proposed
signaling pathway of Up4A.
DISCUSSION
In the present study, we demonstrated the novel finding that
Up4A, a highly potent endothelial-derived contracting factor
liberated from stimulated endothelial cells and a much longer
half-life compared with mononucleotides,24 induces a
phenotypic change of VSMCs to OCCs under the control
of P2Y. This leads to an enhanced vascular calcification in
in vivo and ex vivo assays. Up4A belongs to a heterogeneous
group of dinucleoside polyphosphates, which have been
identified in humans over the last two decades.29 They show
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Figure 4 | Expression of genes associated with differentiation of VSMCs to OCC. Vascular smooth muscle cells (VSMCs) were stimulated
with different concentrations of Up4A (in the absence of CM) for 24 h (a–d), 48 h (e, g–i), or 12 h (f). Expression was measured with
real-time PCR using specific primers and normalization to b-actin as a housekeeping gene. For all panels mean±s.e.m.; *Po0.05 Up4A
versus control. ALP, alkaline phosphatase; Cbfa1, core binding factor a-1; CM, calcifying medium; OCC, osteochondrogenic cell;
OCN, osteocalcin; OPG, osteoprotegerin; OPN, osteopontin; Osx, osterix; Up4A, uridine adenosine tetraphosphate.
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Figure 5 |Cbfa1 protein content. Vascular smooth muscle
cells (VSMCs) were stimulated for 48 h with Up4A (1–100mmol/l).
Cbfa1 protein was detected by western blot technique in the
nuclear protein fraction. (a) Representative western blot.
(b) Quantification of band intensity of four independent
experiments; mean±s.e.m.; *Po0.05 versus control.
Cbfa1, core binding factor a-1; Up4A, uridine adenosine
tetraphosphate.
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multiple effects on the vascular system, for example, as strong
vasoactive mediators, inflammatory or proliferative agents,23
by activation of different purinoceptors. The functions have
been reviewed recently.29 In juvenile hypertensives, Up4A
plasma level is significantly increased compared with age-
matched controls and correlated with the left ventricular
mass and intima/media wall thickness.30 The changes in the
intima/media wall thickness suggested a potential role of
Up4A in structural vascular modifications such as athero-
sclerosis or arteriosclerosis. Only a few reports on mono-
nucleotides, such as ATP/UTP, that interact with osteoblastic
cells exist. Extracellular ATP/UTP can block bone miner-
alization in vitro.31 The interesting question is how Up4A is
able to promote vascular calcification. ALP activity is crucial
during vascular calcification as ALP degrades pyrophosphates
to phosphate. We can show that Up4A significantly increased
ALP activity in VSMCs. In OCCs, molecules regulating
osteoblastic and chondrocytic differentiation, including
Cbfa1,20 Msx2,32 osterix,20 and Sox9,6 have been identified,
whereby Cbfa1 seems to be centrally involved in the
transdifferentiation process. Under different conditions, such
as diabetes mellitus and atherosclerosis, their expression
precedes over calcification.33,34 The essential requirement of
Cbfa1 in osteoblast differentiation is well documented, as
homozygous Cbfa1 knockout mice (Cbfa1/) show a
complete lack of functional osteoblasts and mineralized
bone.35 In addition, overexpression of Cbfa1 leads to
calcification of non-OCCs in vitro.36 Recently, it could be
shown that the origins of calcifying SMCs in matrix Gla
protein-deficient mice predominantly are adult SMCs rather
than progenitor cells.34 In the current report, VSMCs had
undergone lineage reprogramming and expressed OCC
transcription factors such as Cbfa1, Msx2, osterix, and Sox9
after stimulation with Up4A. The potential of VSMCs to
express osteogenic markers has been well documented in a
variety of studies, both in vivo and in vitro.37,38 In accordance
with other studies,37 these cells showed a significant decrease
in the expression of the VSMC lineage proteins a-SMC actin
and SM22a, which we confirmed in this study as well.
Recently, it could be shown that in vitro calcifying conditions
lead to methylation of the SM22a promoter region.39 Many
bone-associated proteins, including OCN,8 OPN,40 OPG,10–15
and ALP9 are differentially expressed in arteriosclerotic
lesions. OCN plasma concentrations are positively associated
with the burden of abdominal aortic calcification in older
women.41 Here, we could show that the expression of OCN
and OPN could be significantly enhanced by stimulation with
Up4A, which seems to be in accordance with other studies
showing that vascular cells undergoing calcification in vitro
express these genes thought to be important for bone
calcification.42,43 Both OPN and OPG are potent inhibitors of
calcification. OPG is normally expressed in blood vessels,16
but is found to be increased in plasma and calcified vessels of
dialysis patients.10,12 Animal studies ruled out a beneficial
effect of OPG.14–16 OPN is normally not expressed there, but
is rapidly induced on injury.44 OPN was found at high levels
in calcified vascular tissue.40 Thus, OPG and OPN may be
naturally occurring inhibitors of cardiovascular calcification
and prevent ectopic mineralization.7 As shown here, Up4A
decreases the OPG expression and increases OPN expression.
From bone remodeling studies, it is known that
osteoblast/osteoclast lineages express different functional P2
receptors with crucial role in the regulation of bone
homeostasis.26 Various studies show that Up4A can activate
P2X and P2Y.24,25 As shown in physiological experiments in
the isolated perfused rat kidney model, Up4A can activate
different purinoceptors: P2X1/3 and P2Y1/2.
24,25 The draw-
back of selective agonists/antagonists hampers the analysis of
individual receptor responses. Except MRS2179, which is
characterized as a selective P2Y1 inhibitor, and MRS2578, a
selective P2Y6 inhibitor,
45 the other investigated inhibitors,
namely suramin, RB-2, and PPADS, are non-selective P2Y
antagonists. Suramin is a competitive P2Y1/2 antagonist and
partly antagonizes P2Y6.
45 RB-2 antagonizes P2Y1/4/6 but
interacts weakly with P2Y2.
45 PPADS is a potent antagonist of
P2Y1/4/6 receptors.
45 For the effects of Up4A investigated here,
the P2Y2/4/6 might be relevant. As published recently, we
found no P2Y1, only a weak expression of the P2Y4, and high
expression of the P2Y2/6 in the VSMCs,
27 which is in
agreement with other studies.23 To prove the hypothesis of
the involvement of P2Y2, we could demonstrate that ATPgS,
a P2Y2 selective agonist, could induce Cbfa1 expression.
Experiments using P2Y2
/ indicated a prominent role of
P2Y2 in the described effects of Up4A. The potential of Up4A
to further increase the calcium content of the aortic rings is
lost in P2Y2
/. Others found evidence for P2Y2 activation in
osteoblastic differentiation of human valve interstitial cells
after ATP/ATPgS treatment by stimulating ALP expression
and activity.46 Furthermore, there is compelling evidence that
nucleotides function via P2Y1/2/4/6 as potent local mediators
in transcriptional signaling in bone.26 Others show an
upregulation of P2Y2/6 responsible for a phenotypic switch
of contractile VSMCs to synthetic VSMCs,47 which could not
be seen in our experiments using Up4A (Supplementary
Figure S1 online). The transcriptional activity of Cbfa1 is
either accompanied by a posttranscriptional modification or
through an accessory factor.48 Phosphorylation of Cbfa1 is
essential for DNA binding. MAPK-dependent phosphoryla-
tion cascade might regulate Cbfa1 activity. As shown
recently,27 Up4A could activate the MAPK MEK and its
downstream kinase ERK1/2. ATP and UTP induced the
equipotent MAPK pathway through P2Y2 activation.
49 We
demonstrated that suramin and PPADS pretreatment dimin-
ished the Up4A-induced phosphorylation of MEK/ERK1/2.
In line with this finding, inhibition with PD98059/U0126
reduced Cbfa1 expression. These findings are similar to those
of others who also identified ERK as important for Cbfa1
phosphorylation.48 Other studies with truncated protein
variants of Cbfa1 identified C-terminal prolin/serine/threo-
nine-rich domains, which are responsible for MAPK binding
on Cbfa1 for phosphorylation.50 It could be shown that the
Cbfa1 promoter has functional binding sites for Cbfa1 itself,
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so that auto-regulatory processes are involved in Cbfa1
expression.51 This might be one explanation why we found a
decreased Cbfa1 expression after PD98059/U0126 co-treat-
ment. This in vitro study attenuates the potential role of
Up4A in enhancing vascular calcification of arteries via a
P2Y-involved pathway. Cbfa1 is activated by Up4A for the
phenotypic change of VSMCs. In addition, MAPK phos-
phorylation has an important regulatory role. There were
hints in the literature for the activation of the Wnt pathway,
especially Wnt3a and Wnt7a, in the calcification process.28
Here, we show that Up4A stimulation of VSMCs results in
an increase of Wnt3a and Wnt7a mRNA expression. Fur-
ther studies are necessary to address the specific role of the
pathway.
It would be interesting to study the effects of P2Y
activation by Up4A in an in vivo model, but this is currently
not possible. Plasma concentrations of Up4A are low, and
tested concentrations of Up4A in our models are about 10- to
100-fold higher than plasma concentrations. Arteriosclerosis
progression is mainly a local phenomenon in large and
muscular vessels and a possible consequence of high local
concentrations of pro-arteriosclerotic substances such as
Up4A. It is very well documented that nucleotides are locally
secreted in high amounts, which exceed plasma concentra-
tion up to 1000-fold.52 The method to generate an animal
model with increased local concentrations in certain defined
vessel areas is currently not available. An increased plasma
concentration gives only an impression of an increased local
production of nucleotides.
In summary, we show for the first time the importance
of the purinergic system, especially Up4A and P2Y, for
the initiation of a transdifferentiation of VSMCs.
Therefore, besides the known potent influence on the
hemodynamic properties and vascular biology, the purinergic
system seems to have novel and potential effects on vascular
calcification.
MATERIALS AND METHODS
Patient recruitment
The study was approved by the local ethics committee, and
informed consent was obtained from all patients. Patients enrolled
in this study had undergone hemodialysis with a median of 32±6
months. Subjects with normal renal function were used as the
control group. For further information see Supplementary Material
online. The clinical and biochemical characteristics of patients and
control subjects are given in Table 1.
Measurement of Up4A plasma concentration
The extraction of human plasma and the subsequent Up4A
quantification was performed as described previously.30
Animals
In this study, Wistar–Kyoto rats were used for isolation of VSMCs,
and aortic rings for ex vivo experiments. P2Y/ mice (strain name:
B6.129P2-P2ry2tm1Bhk/J) were purchased from the Jackson Labora-
tory (Bar Harbor, ME). All animal experiments were conducted in
accordance with the guidelines for the Care and Use of Laboratory
Animals, and were approved by individual Animal Care Committees
at the Landesamt fu¨r Gesundheit und Soziales, Berlin.
Cell culture
VSMCs were isolated by explant outgrowth from thoracic aortas of
rats as described previously.53 Cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal calf serum
and antibiotics. Passages 3–6 were used for the experiments in this
study. For induction of calcification, Dulbecco’s modified Eagle’s
medium containing 4.5 g/l glucose supplemented with 15% fetal calf
serum, 10mmol/l sodium pyruvate, 50mg/ml ascorbic acid, and
10mmol/l b-glycerol phosphate (CM) were used.
In vitro calcification and ex vivo calcification
In vitro calcification of VSMCs was induced as described
previously.54 Briefly, confluent cells were incubated in CM. For
ex vivo experiments, aorta was explanted from rats or mice,
adventitia was carefully removed, and aorta was cut into small rings.
After the stimulation procedure, one ring of each stimulation
approach was fixed in 4% paraformaldehyde for histological
analysis. The initial day of culture in CM was defined as day 0.
The medium was changed every 3 days.
Alizarin red and von Kossa staining
Cells were fixed with 4% buffered formalin, washed with phosphate-
buffered saline (PBS) and distilled deionized water, and treated
with 2% Alizarin solution (pH 4.2) for 20min. Paraffin-embedded
aortic rings were serially cut into pieces of 2 mm, deparaffinized,
and stained with Alizarin red or von Kossa stain. Calcification status
was imaged using an Axiovert 2000 microscope (Zeiss, Jena,
Germany).
Quantification of calcium content
VSMCs and aortic rings were decalcified with 0.6mol/l HCl for 24 h,
respectively. Calcium content of the supernatants was determined
using the O-cresolphthalein complexone method (Calcium C-test,
Wako Chemicals, Neuss, Germany) and measured photometrically
at 570 nm. After washing the cells with PBS, they were solubilized in
0.1mol/l NaOH/0.1% SDS, and the protein content was measured
with the bicinchoninic acid (BCA) protein assay kit (Pierce,
Rockford, IL). The calcium content of the cell layer was normalized
to protein content or dry weight of aortic rings.
Table 1 | Clinical and biochemical characterization of patients
undergoing dialysis treatment and healthy control subjects
Dialysis patients
(n=17)
Controls
(n=15)
Age (years) 69 (66–82) 57 (45–78)
Sex (male/female) 8/9 6/9
Body weight (kg) 76.4 (62–92) 72.5 (51–89)
Duration of dialysis (months) 32±6 0
Systolic blood pressure (mmHg) 132 (111–156) 129 (108–142)
Diastolic blood pressure (mmHg) 73 (61–94) 72 (62–93)
Serum creatinine (mg/dl) 7.4 (5.6–9.2) 0.8 (0.6–1.0)
Smoking 3/17 0
Diabetes 4/17 0
Coronary heart disease 3/17 0
Hypertension 14/17 0
Data are given as median and its range.
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Measurement of ALP activity
After stimulation, cells were scraped in 0.2% triton/PBS containing
protease inhibitors. The activity of ALP was measured by using
pNPP as substrate and a commercially available kit from Gentaur
(Kampenhout, Belgium) according to the manufacturer’s protocol.
Protein concentration was determined with a BCA protein assay kit
(Pierce).
Flow cytometry analysis
The cells were collected and washed in PBS, spin down, and
resuspended in 500 ml PBS. A volume of 5 ml anti-a-actin-FITC
antibody (Sigma, St Louis, MO) was added and incubated for
20min at room temperature in the dark. Thereafter, the cells were
washed with PBS, resuspended in PBS, and analyzed by flow
cytometry (Epics XL4, Beckman Coulter, Krefeld, Germany). An
isotype control for the antibody was run in each experiment.
Immunofluorescence staining
The cells were seeded in eight-well slides (Ibidi, Martinsried,
Germany), fixed with ice-cold ethanol, and blocked with 5% bovine
serum albumin/PBS for 1 h at room temperature. Further, the cells
were incubated with anti-a-actin-FITC antibody (Sigma) for 1 h in
the dark. After washing with PBS, the cells were incubated for a few
minutes with DAPI (Sigma) for nuclear staining and then washed
again with PBS. For image acquisition, a fluorescence microscope
with the Axio Vision (Zeiss) software was used.
Measurement of gene expression
Serum-starved cells (24 h) were used for stimulation experiments as
indicated. After cell stimulation, the medium was withdrawn, the
cells washed with ice-cold PBS and scraped, as well as lysed into RLT
cell lysis buffer (Qiagen, Chatsworth, CA). RNA was isolated with
the RNeasy Mini kit (Qiagen), according to the manufacturer’s
instructions. A measure of 2 mg of total RNA from each sample was
reversed transcribed using the High-Capacity cDNA Archive Kit
(Applied Biosystems, Foster City, CA). Levels of rat mRNA
expression were determined by quantitative real-time PCR per-
formed with reagents kits obtained from Applied Biosystems in the
Realplex Detection System (Eppendorf, Hamburg, Germany). The
primers were synthesized by TibMolBiol (Berlin, Germany). Primer
sequences are summarized in Supplementary Materials online.
Quantification of gene expression was normalized to actin as a
housekeeping gene.
Western blot analysis
VSMCs were starved in serum-free medium for 24 h. The cells were
stimulated with Up4A (10 mmol/l) for 24 h. For preparation of
cytoplasmic and nuclear protein extracts from the cultured and
stimulated cells, the NE-PER Nuclear and Cytoplasmic Extraction
Reagents kit (Pierce) were used according to the manufacturer’s
instructions. The protein concentration was measured with a BCA
assay kit (Pierce). Equal amounts of protein were loaded and
separated by 12% SDS-PAGE, followed by transfer to a polyvinyli-
dene difluoride membrane (Bio-Rad, Munich, Germany). The
membrane was incubated with a specific rabbit anti-Cbfa1 antibody
(1:1000, Aviva Systems Biology, San Diego, CA) overnight at 4 1C
and, after washing, with HRP-conjugated anti-rabbit IgG antibody
(1:5000, KPL, Gaithersburg, MD) for 1 h at room temperature. The
bands were detected using Super Signal Dura West Substrate (Pierce)
and the Chemi-Smart (Vilber Lourmat, Torcy, France) imaging
system. The density of the corresponding bands was measured
quantitatively using the Bio1D Image software (Vilber Lourmat).
Phosphoprotein detection
Serum-starved VSMCs were stimulated with Up4A for the indicated
time points, harvested with ice-cold cell lysis buffer (Bio-Rad),
centrifuged for 20min at 4 1C and 13,000 r.p.m., and the super-
natant was spiked with equal amounts of assay buffer (Bio-Rad).
Protein amount of the lysates were determined with the BCA assay
kit (Pierce). Determination of phosphoprotein and total protein was
performed using Luminex technology with the phosphoprotein
detection assay (Bio-Rad).
Statistical analysis
Data are presented as means±s.e.m. from at least five separate
experiments, or as results, representative for at least five repetitions,
unless otherwise indicated. Calculations were performed with
GraphPad Prism software (Version 5.03, La Jolla, CA). When 42
groups are included, a Kruskal–Wallis test was performed. If a
significant difference is detectable, a Mann–Whitney U-test was
performed, and Bonferroni correction was performed if applicable.
P-values o0.05 were considered significant.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
This work was supported by Deutsche Forschungsgemeinschaft
(DFG 972/11-2; MvdG, JJ), Sonnenfeld Stiftung (JP), Nationales
Genomforschungsnetzwerk (JJ), and Syskid (JJ).
SUPPLEMENTARY MATERIAL
Figure S1. mRNA expression of P2Y subtypes in rat VSMCs.
Figure S2. Cell viability.
Figure S3. Wnt mRNA expression.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Persy V, D’Haese P. Vascular calcification and bone disease: the
calcification paradox. Trends Mol Med 2009; 15: 405–416.
2. Demer LL, Tintut Y. Vascular calcification: pathobiology of a multifaceted
disease. Circulation 2008; 117: 2938–2948.
3. Shroff RC, McNair R, Figg N et al. Dialysis accelerates medial vascular
calcification in part by triggering smooth muscle cell apoptosis.
Circulation 2008; 118: 1748–1757.
4. London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in
end-stage renal disease: impact on all-cause and cardiovascular mortality.
Nephrol Dial Transplant 2003; 18: 1731–1740.
5. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and
morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:
2208–2218.
6. Tyson KL, Reynolds JL, McNair R et al. Osteo/chondrocytic transcription
factors and their target genes exhibit distinct patterns of expression in
human arterial calcification. Arterioscler Thromb Vasc Biol 2003; 23:
489–494.
7. Giachelli CM. Ectopic calcification: gathering hard facts about soft tissue
mineralization. Am J Pathol 1999; 154: 671–675.
8. Levy RJ, Gundberg C, Scheinman R. The identification of the vitamin K-
dependent bone protein osteocalcin as one of the gamma-
carboxyglutamic acid containing proteins present in calcified
atherosclerotic plaque and mineralized heart valves. Atherosclerosis 1983;
46: 49–56.
9. Mori K, Shioi A, Jono S et al. Dexamethasone enhances in vitro vascular
calcification by promoting osteoblastic differentiation of vascular smooth
muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 2112–2118.
264 Kidney International (2012) 81, 256–265
or ig ina l a r t i c l e M Schuchardt et al.: Up4A and vascular calcification
10. Schoppet M, Al-Fakhri N, Franke FE et al. Localization of osteoprotegerin,
tumor necrosis factor-related apoptosis-inducing ligand, and receptor
activator of nuclear factor-kappaB ligand in Monckeberg’s sclerosis and
atherosclerosis. J Clin Endocrinol Metab 2004; 89: 4104–4112.
11. Moe SM, Chen NX. Pathophysiology of vascular calcification in chronic
kidney disease. Circ Res 2004; 95: 560–567.
12. Nitta K, Akiba T, Uchida K et al. The progression of vascular calcification
and serum osteoprotegerin levels in patients on long-term hemodialysis.
Am J Kidney Dis 2003; 42: 303–309.
13. Nitta K, Akiba T, Uchida K et al. Serum osteoprotegerin levels and the
extent of vascular calcification in haemodialysis patients. Nephrol Dial
Transplant 2004; 19: 1886–1889.
14. Morony S, Tintut Y, Zhang Z et al. Osteoprotegerin inhibits vascular
calcification without affecting atherosclerosis in ldlr(/) mice.
Circulation 2008; 117: 411–420.
15. Bennett BJ, Scatena M, Kirk EA et al. Osteoprotegerin inactivation
accelerates advanced atherosclerotic lesion progression and calcification
in older ApoE/ mice. Arterioscler Thromb Vasc Biol 2006; 26:
2117–2124.
16. Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice
develop early onset osteoporosis and arterial calcification. Genes Dev
1998; 12: 1260–1268.
17. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney
disease. J Am Soc Nephrol 2008; 19: 213–216.
18. Neven E, Dauwe S, De Broe ME et al. Endochondral bone formation is
involved in media calcification in rats and in men. Kidney Int 2007; 72:
574–581.
19. Wilkie AO, Tang Z, Elanko N et al. Functional haploinsufficiency of the
human homeobox gene MSX2 causes defects in skull ossification. Nat
Genet 2000; 24: 387–390.
20. Igarashi M, Kamiya N, Hasegawa M et al. Inductive effects of
dexamethasone on the gene expression of Cbfa1, Osterix and bone
matrix proteins during differentiation of cultured primary rat osteoblasts.
J Mol Histol 2004; 35: 3–10.
21. Di Virgilio F, Solini A. P2 receptors: new potential players in
atherosclerosis. Br J Pharmacol 2002; 135: 831–842.
22. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol
Rev 1998; 50: 413–492.
23. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and
disease. Purinergic Signal 2008; 4: 1–20.
24. Jankowski V, Tolle M, Vanholder R et al. Uridine adenosine
tetraphosphate: a novel endothelium- derived vasoconstrictive factor.
Nat Med 2005; 11: 223–227.
25. Tolle M, Schuchardt M, Wiedon A et al. Differential effects of uridine
adenosine tetraphosphateon purinoceptors in the rat isolated perfused
kidney. Br J Pharmacol 2010; 161: 530–540.
26. Bowler WB, Buckley KA, Gartland A et al. Extracellular nucleotide
signaling: a mechanism for integrating local and systemic responses in
the activation of bone remodeling. Bone 2001; 28: 507–512.
27. Schuchardt M, Prufer J, Prufer N et al. The endothelium-derived
contracting factor uridine adenosine tetraphosphate induces P2Y(2)-
mediated pro-inflammatory signaling by monocyte chemoattractant
protein-1 formation. J Mol Med 2011; 89: 799–810.
28. Al-Aly Z, Shao J-S, Lai C-F et al. Aortic Msx2-Wnt calcification cascade is
regulated by TNF-{alpha} dependent signals in diabetic Ldlr/mice.
Arterioscler Thromb Vasc Biol 2007; 27: 2589–2596.
29. Jankowski V, van der Giet M, Mischak H et al. Dinucleoside
polyphosphates: strong endogenous agonists of the purinergic system.
Br J Pharmacol 2009; 157: 1142–1153.
30. Jankowski V, Meyer AA, Schlattmann P et al. Increased uridine adenosine
tetraphosphate concentrations in plasma of juvenile hypertensives.
Arterioscler Thromb Vasc Biol 2007; 27: 1776–1781.
31. Hoebertz A, Arnett TR, Burnstock G. Regulation of bone resorption and
formation by purines and pyrimidines. Trends Pharmacol Sci 2003; 24:
290–297.
32. Towler DA, Bidder M, Latifi T et al. Diet-induced diabetes activates
an osteogenic gene regulatory program in the aortas of low
density lipoprotein receptor-deficient mice. J Biol Chem 1998; 273:
30427–30434.
33. Moe SM, O’Neill KD, Duan D et al. Medial artery calcification in ESRD
patients is associated with deposition of bone matrix proteins. Kidney Int
2002; 61: 638–647.
34. Speer MY, Yang HY, Brabb T et al. Smooth muscle cells give rise to
osteochondrogenic precursors and chondrocytes in calcifying arteries.
Circ Res 2009; 104: 733–741.
35. Komori T, Yagi H, Nomura S et al. Targeted disruption of Cbfa1 results in a
complete lack of bone formation owing to maturational arrest of
osteoblasts. Cell 1997; 89: 755–764.
36. Zheng H, Guo Z, Ma Q et al. Cbfa1/osf2 transduced bone marrow stromal
cells facilitate bone formation in vitro and in vivo. Calcif Tissue Int 2004;
74: 194–203.
37. Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic
transition associated with calcification: upregulation of Cbfa1 and
downregulation of smooth muscle lineage markers. Circ Res 2001; 89:
1147–1154.
38. Reynolds JL, Joannides AJ, Skepper JN et al. Human vascular smooth
muscle cells undergo vesicle-mediated calcification in response to
changes in extracellular calcium and phosphate concentrations: a
potential mechanism for accelerated vascular calcification in ESRD. J Am
Soc Nephrol 2004; 15: 2857–2867.
39. de Oca AM, Maduen˜o JA, Martinez-Moreno JM et al. High-phosphate-
induced calcification is related to SM22a promoter methylation
in vascular smooth muscle cells. J Bone Miner Res 2010; 25:
1996–2005.
40. Wada T, McKee MD, Steitz S et al. Calcification of vascular smooth
muscle cell cultures: inhibition by osteopontin. Circ Res 1999; 84:
166–178.
41. Parker BD, Bauer DC, Ensrud KE et al. Association of osteocalcin and
abdominal aortic calcification in older women: the study of osteoporotic
fractures. Calcif Tissue Int 2010; 86: 185–191.
42. Proudfoot D, Skepper JN, Shanahan CM et al. Calcification of human
vascular cells in vitro is correlated with high levels of matrix Gla protein
and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol
1998; 18: 379–388.
43. Schor AM, Allen TD, Canfield AE et al. Pericytes derived from the retinal
microvasculature undergo calcification in vitro. J Cell Sci 1990; 97(Pt 3):
449–461.
44. Giachelli CM, Bae N, Almeida M et al. Osteopontin is elevated during
neointima formation in rat arteries and is a novel component of human
atherosclerotic plaques. J Clin Invest 1993; 92: 1686–1696.
45. von Kugelgen I. Pharmacological profiles of cloned mammalian P2Y-
receptor subtypes. Pharmacol Ther 2006; 110: 415–432.
46. Osman L, Chester AH, Amrani M et al. A novel role of extracellular
nucleotides in valve calcification: a potential target for atorvastatin.
Circulation 2006; 114: I566–I572.
47. Wang L, Andersson M, Karlsson L et al. Increased mitogenic and
decreased contractile P2 receptors in smooth muscle cells by shear stress
in human vessels with intact endothelium. Arterioscler Thromb Vasc Biol
2003; 23: 1370–1376.
48. Xiao G, Jiang D, Thomas P et al. MAPK pathways activate and
phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol
Chem 2000; 275: 4453–4459.
49. Soltoff SP, Avraham H, Avraham S et al. Activation of P2Y2 receptors by
UTP and ATP stimulates mitogen-activated kinase activity through a
pathway that involves related adhesion focal tyrosine kinase and protein
kinase C. J Biol Chem 1998; 273: 2653–2660.
50. Franceschi RT, Ge C, Xiao G et al. Transcriptional regulation of osteoblasts.
Ann N Y Acad Sci 2007; 1116: 196–207.
51. Ducy P. Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 2000;
219: 461–471.
52. Jankowski V, Gunthner T, Herget-Rosenthal S et al. Dinucleoside
polyphosphates and uremia. Semin Dial 2009; 22: 396–399.
53. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell:
proliferation of smooth muscle is a key event in the genesis of the lesions
of atherosclerosis. Science 1973; 180: 1332–1339.
54. Shioi A, Nishizawa Y, Jono S et al. Beta-glycerophosphate accelerates
calcification in cultured bovine vascular smooth muscle cells. Arterioscler
Thromb Vasc Biol 1995; 15: 2003–2009.
Kidney International (2012) 81, 256–265 265
M Schuchardt et al.: Up4A and vascular calcification o r ig ina l a r t i c l e
